Literature DB >> 10809287

Effects of vasopressin and epinephrine on splanchnic blood flow and renal function during and after cardiopulmonary resuscitation in pigs.

W G Voelckel1, K H Lindner, V Wenzel, J Bonatti, H Hangler, C Frimmel, E Künszberg, W Lingnau.   

Abstract

OBJECTIVE: To compare the effects of vasopressin versus epinephrine on splanchnic blood flow during and after cardiopulmonary resuscitation (CPR), and to evaluate the effects of these vasopressors on renal function in the postresuscitation phase.
DESIGN: Prospective, randomized laboratory investigation using an established porcine CPR model with instrumentation for continuous measurement of splanchnic and renal blood flow.
SETTING: University hospital experimental laboratory.
SUBJECTS: A total of 12 anesthetized, 12- to 16-wk-old domestic pigs weighing 30-35 kg.
INTERVENTIONS: After 4 mins of cardiac arrest, and 3 mins of CPR, 12 pigs were randomly assigned to receive either 0.4 units/kg vasopressin (n = 6) or 45 microg/kg epinephrine (n = 6). Defibrillation was performed 5 mins after drug administration; all animals were observed for 6 hrs after return of spontaneous circulation (ROSC).
MEASUREMENTS AND MAIN RESULTS: Mean +/- SEM superior mesenteric artery blood flow was significantly (p < .05) lower after vasopressin compared with epinephrine at 90 secs after drug administration (13+/-3 vs. 129+/-33 mL/min); at 5 mins after drug administration (31+/-18 vs. 155+/-39 mL/min); at 5 mins after ROSC (332+/-47 vs. 1087+/-166 mL/min); and at 15 mins after ROSC (450+/-106 vs. 1130+/-222 mL/min); respectively. Mean +/- SEM left renal and hepatic artery blood flow after ROSC was comparable in both groups ranging between 120-290 mL/min (renal blood flow), and 150-360 mL/min (hepatic blood flow), respectively. Median urine output after ROSC showed no difference between groups, and highest values (180-220 mL/hr) were observed in the first 60 mins after ROSC. Median calculated glomerular filtration rate showed no difference between groups with values ranging between 30 and 80 mL/min in the postresuscitation phase. Calculated fractional sodium excretion and osmolar relationship between urea and plasma indicated no evidence for renal tubular dysfunction.
CONCLUSIONS: In the early postresuscitation phase, superior mesenteric blood flow was temporarily impaired by vasopressin in comparison with epinephrine. With respect to renal blood flow and renal function after ROSC, there was no difference between either vasopressor given during CPR. Vasopressin given during CPR did not result in an antidiuretic state in the postresuscitation phase.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10809287     DOI: 10.1097/00003246-200004000-00029

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  4 in total

Review 1.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Drug administration in animal studies of cardiac arrest does not reflect human clinical experience.

Authors:  Joshua C Reynolds; Jon C Rittenberger; James J Menegazzi
Journal:  Resuscitation       Date:  2007-03-13       Impact factor: 5.262

3.  Evaluation of capillary leakage after vasopressin resuscitation in a hemorrhagic shock model.

Authors:  Roberto Bini; Osvaldo Chiara; Stefania Cimbanassi; Giorgio Olivero; Antonella Trombetta; Paolo Cotogni
Journal:  World J Emerg Surg       Date:  2018-03-05       Impact factor: 5.469

4.  The association of early diarrhea after successful resuscitation following out-of-hospital cardiac arrest with neurological outcome: A retrospective observational study.

Authors:  Christoph Schriefl; Philipp Steininger; Christian Clodi; Matthias Mueller; Michael Poppe; Florian Ettl; Alexander Nuernberger; Juergen Grafeneder; Heidrun Losert; Michael Schwameis; Michael Holzer; Fritz Sterz; Christian Schoergenhofer
Journal:  Medicine (Baltimore)       Date:  2021-12-10       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.